1. Kobayashi, Yuta, Bustos, Matias A, Shoji, Yoshiaki, Shiloh, Yosef, Hoon, Dave S B. 2022. Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor. In Cells, 11, . doi:10.3390/cells11203311. https://pubmed.ncbi.nlm.nih.gov/36291176/
2. Edens, Brittany M, Yan, Jianhua, Miller, Nimrod, Siddique, Teepu, Ma, Yongchao C. 2017. A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis. In eLife, 6, . doi:10.7554/eLife.25453. https://pubmed.ncbi.nlm.nih.gov/28463112/
3. Murakami, Tomohiro, Shoji, Yoshiaki, Nishi, Tomohiko, Hoon, Dave S B, Bustos, Matias A. 2021. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. In Molecular oncology, 15, 1069-1087. doi:10.1002/1878-0261.12929. https://pubmed.ncbi.nlm.nih.gov/33605536/
4. Yu, Yan, Xu, Penglin, Cui, Guangying, Chen, Xiaolong, Bao, Jie. 2020. UBQLN4 promotes progression of HCC via activating wnt-β-catenin pathway and is regulated by miR-370. In Cancer cell international, 20, 3. doi:10.1186/s12935-019-1078-5. https://pubmed.ncbi.nlm.nih.gov/31911755/
5. Tang, Xiaolong, Liang, Yahang, Sun, Guorui, Qu, Hui, Gao, Peng. 2021. UBQLN4 is activated by C/EBPβ and exerts oncogenic effects on colorectal cancer via the Wnt/β-catenin signaling pathway. In Cell death discovery, 7, 398. doi:10.1038/s41420-021-00795-4. https://pubmed.ncbi.nlm.nih.gov/34930912/
6. He, Li, Chen, Heng, Ruan, Bin, Fu, Yulun, Zou, Rui. 2024. UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway. In Journal of cancer research and clinical oncology, 150, 335. doi:10.1007/s00432-024-05862-8. https://pubmed.ncbi.nlm.nih.gov/38969831/
7. Suzuki, Rigel, Kawahara, Hiroyuki. 2016. UBQLN4 recognizes mislocalized transmembrane domain proteins and targets these to proteasomal degradation. In EMBO reports, 17, 842-57. doi:10.15252/embr.201541402. https://pubmed.ncbi.nlm.nih.gov/27113755/
智鼠故事 
